SHR-1703

• Description :

  SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1].

• UNSPSC :

  12352203

• Target :

  Interleukin Related

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• References & Citations :

  [1]Yang L, et al. Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study. Expert Opin Investig Drugs. 2024 Jul;33 (7) :741-752.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported

• Isoform :

  IL-5